Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A., Léna, H., Monnet, I., Rothschild, S., Cappuzzo, F., Besse, B., Thiberville, L., Rouvière, D., Dziadziuszko, R., Smit, E., Wolf, J., Spirig, C., Pecuchet, N., Leenders, F., Heuckmann, J., Diebold, J., Milia, J., Thomas, R. and Gautschi, O. (2015) Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results from the EUROS1 Cohort. Journal of Clinical Oncology, 33, 992-999. https://doi.org/10.1200/JCO.2014.58.3302

has been cited by the following article:

• TITLE: Biomarker Driven Cancer Therapeutics: Existing Tools and Remaining Gaps

  AUTHORS: Sasi Shanmugam Senga, Jemma Arakelyan

  KEYWORDS: Cancer Biomarkers, Breast Cancer, Lung Cancer

  JOURNAL NAME: Open Access Library Journal, Vol.7 No.7, July 31, 2020

  ABSTRACT: Advancements in technology such as proteomics, genomics have led to the concept of personalized medicine wherein the integration of biomarkers into clinic directs cancer therapeutics. Traditional staging has a stochastic element which can only predict the outcome without actual consideration of intrapatient heterogeneity. In this review, we will look at the biomarkers that prove to be valuable tools for the personalization of cancer therapeutics among lung and breast cancer patients.